Is it appropriate to give Megace (medroxyprogesterone acetate) 400 mg per 10 mL, 2 teaspoons orally twice daily?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Megace Dose Assessment: 400mg/10mL, 2 teaspoons PO BID

The prescribed dose of Megace 400mg/10mL, 2 teaspoons (10mL = 800mg) twice daily for a total of 1600mg/day is NOT appropriate and exceeds recommended dosing.

Correct Dosing Based on FDA Label and Guidelines

The FDA-approved formulation you're describing appears to be Megace ES (concentrated formula at 125mg/mL), not the regular suspension 1. This is a critical distinction:

Megace ES (125mg/mL concentration):

  • Recommended dose: 625mg/day = 5mL (1 teaspoon) ONCE daily 1
  • Your order of 2 teaspoons BID would deliver 2500mg/day - approximately 4 times the recommended dose

If using regular Megace suspension (40mg/mL):

  • Standard effective dose: 400-800mg/day 1
  • Your order of 10mL BID from a 40mg/10mL suspension would only deliver 800mg/day total, which falls within range

Evidence-Based Dosing Recommendations

For medroxyprogesterone acetate (MPA) as appetite stimulant:

  • Minimum effective dose: 200mg/day 2
  • Studied range: 300-1200mg/day 3
  • Most trials used 300-500mg twice daily for 6-12 weeks 3

For megestrol acetate (different drug):

  • Minimum effective: 160mg/day 2
  • Optimal dose: 480-800mg/day 3
  • No additional benefit above 480mg/day 2

Critical Safety Concerns

You must be aware of serious adverse effects, particularly at high doses:

  • Thromboembolic events: 1 in 6 patients 4
  • Increased mortality: 1 in 23 patients 4
  • Edema, adrenal insufficiency 5
  • Impotence, vaginal spotting 3

The 2017 ESPEN guidelines explicitly state: "suggest considering progestins to increase appetite...but to be aware of potential serious side effects (e.g. thromboembolism)" 3.

Recommended Action

HOLD this order and clarify:

  1. Which formulation is being used (Megace ES 125mg/mL vs regular 40mg/mL)?
  2. Intended indication (appetite stimulation in cancer cachexia vs other)?
  3. Correct the dose:
    • If Megace ES: 625mg (5mL) once daily
    • If regular MPA suspension: 400-500mg (10-12.5mL) once or twice daily
    • Maximum studied dose: 1200mg/day, but no benefit above 800mg/day

Clinical Pearls

  • MPA increases appetite but does NOT increase lean body mass - only fat mass increases 3
  • Effect on quality of life is inconsistent 3
  • Should only be used in advanced cancer patients with months-to-weeks life expectancy where appetite is important for quality of life 4
  • Monitor for thromboembolism, edema, hyperglycemia (especially in dialysis patients) 6, 7
  • Recent data shows increased meningioma risk with prolonged MPA exposure (>4 years or age >31) 8, 9

The dose as written is unsafe and requires immediate clarification and correction.

References

Guideline

palliative care version 1.2016.

Journal of the National Comprehensive Cancer Network : JNCCN, 2016

Guideline

management of cancer cachexia: asco guideline.

Journal of Clinical Oncology, 2020

Research

The effects of megestrol acetate on nutritional parameters in a dialysis population.

Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation, 2000

Research

Megestrol acetate in a moderate dose for the treatment of malnutrition-inflammation complex in maintenance dialysis patients.

Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation, 2005

Related Questions

What dose of oral medroxyprogesterone acetate (Provera) should be used for medical management?
Is it appropriate to initiate medroxyprogesterone acetate (Depo‑Provera) injection in a sexually active 15‑year‑old female seeking hormonal contraception with no contraindications?
Should an 18-year-old who has been receiving the Depo-Provera (medroxyprogesterone acetate) injection for three years undergo a bone-density test?
What checklist should be used before initiating Depo‑Provera (medroxyprogesterone acetate) contraception, including pregnancy testing, contraindications, baseline assessments, counseling points, and follow‑up requirements?
A patient who has been using depot medroxyprogesterone acetate (DMPA) injection, is 11 weeks and 3 days since her last injection, meets UKMEC criteria for combined hormonal contraception (CHC), and wishes to start a combined transdermal contraceptive patch today; how many days will it take for the patch to become effective?
How should I explain to my patient that their FibroScan shows early liver fibrosis (stiffness ≈11 kPa) and moderate steatosis (CAP ≈300 dB/m), and advise on weight loss, alcohol avoidance, control of diabetes, cholesterol, blood pressure, and follow‑up?
What are the contraindications for venlafaxine?
What is the recommended starting dose of salmon calcitonin for an adult with osteoporosis and for acute hypercalcemia, and how should the dose be adjusted in renal impairment?
How should I dose omega‑3 supplements with capsule strengths of 350 mg, 235 mg, 90 mg, and 597 mg to achieve the recommended daily EPA + DHA intake?
What is the recommended duration of postpartum magnesium sulfate (MgSO4) infusion for seizure prophylaxis in women with severe pre‑eclampsia, and are there studies comparing a 12‑hour versus a 24‑hour regimen?
Does Hashimoto's thyroiditis resolve?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.